Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 3/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.38 |
| ▸ | FABP7 | O15540 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MDM4 | O15151 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30416398 | 1.00 | PTGIR (0.41) | PTGIRFABP5FABP7HTTKMT2A | |
| SCHEMBL19668362 | 1.00 | PTGIR (0.41) | PTGIRFABP5FABP7HTTKMT2A | |
| SCHEMBL31210304 | 1.00 | PTGIR (0.41) | PTGIRFABP5FABP7HTTKMT2A | |
| SCHEMBL1905118 | 0.89 | FABP5 (0.44) | FABP5FABP7KMT2AMDM4TP53 | |
| SCHEMBL19668361 | 0.88 | FABP5 (0.40) | FABP5FABP7KMT2AMDM4TP53 | |
| SCHEMBL1885672 | 0.88 | FABP5 (0.40) | FABP5FABP7KMT2AMDM4TP53 | |
| SCHEMBL5494109 | 0.81 | FABP5 (0.43) | PTGIRFABP5FABP7KMT2AMDM4 | |
| SCHEMBL3902426 | 0.81 | GPBAR1 (0.41) | — | |
| SCHEMBL6629444 | 0.81 | FABP5 (0.40) | PTGIRFABP5FABP7KMT2AMDM4 | |
| SCHEMBL18301508 | 0.81 | FABP5 (0.39) | FABP5FABP7KMT2AMDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12098218-B2 | Process for the manufacture of degarelix and its intermediates | Fresenius Kabi iPSUM S.r.l (IT) | 2024-09-24 | — | — | US | disclosed |
| US-11773150-B2 | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors | MERCK SHARP & DOHME LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-20220177521-A1 | PROCESS FOR THE PREPARATION OF DEGARELIX | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-06-09 | — | — | US | disclosed |
| US-11332495-B2 | Process for the preparation of Degarelix acetate and Degarelix acetate-mannitol premix | RK Pharma Solutions LLC (US) | 2022-05-17 | — | — | US | disclosed |
| EP-3981781-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | Fresenius Kabi iPSUM S.r.l. (IT) | 2022-04-13 | — | — | EP | disclosed |
| US-20220033443-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | Fresenius Kabi iPSUM S.r.l (IT) | 2022-02-03 | — | — | US | disclosed |
| US-20210094984-A1 | Process for the preparation of Degarelix acetate and Degarelix acetate-mannitol premix | CITIBANK, N.A. | 2021-04-01 | — | — | US | disclosed |
| US-20200392197-A1 | ANTIBODY PEPTIDE CONJUGATES THAT HAVE AGONIST ACTIVITY AT BOTH THE GLUCAGON AND GLUCAGON-LIKE PEPTIDE 1 RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2020-12-17 | — | — | US | disclosed |
| US-10800826-B2 | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors | MERCK SHARP & DOHME CORP. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10683334-B2 | Aqueously soluble and chemically stable glucagon peptides | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-06-16 | — | — | US | disclosed |
| EP-1226146-A2 | QUINOLINE AND NAPHTHYRIDINE CARBOXYLIC ACID ANTIBACTERIALS | ABBOTT LABORATORIES (US) | 2002-07-31 | — | — | EP | disclosed |
| US-20020049223-A1 | Quinoline and naphthyridine carboxylic acid antibacterials | ABBOTT LABORATORIES | 2002-04-25 | — | — | US | disclosed |
| WO-2001058471-A2 | NOVEL AMINO ACID AND PEPTIDE INHIBITORS OF STAPHYLOCOCCUS VIRULENCE | INTERMUNE, INC. (US) | 2001-08-16 | — | — | WO | disclosed |
| WO-2001032655-A2 | QUINOLINE AND NAPHTHYRIDINE CARBOXYLIC ACID ANTIBACTERIALS | ABBOTT LABORATORIES (US) | 2001-05-10 | — | — | WO | disclosed |
| US-6229011-B1 | BINDING INHIBITORS BETWEEN VASCULAR ADHESION MOLECULE-1 AND ALPHA. BETA.INTEGRIN; USEFUL FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES SUCH AS MULTIPLE SCLEROSIS, ASTHMA, AND INFLAMMATORY BOWEL DISEASE | HOFFMAN-LA ROCHE INC. | 2001-05-08 | — | — | US | disclosed |
| EP-1005445-A1 | N-ALKANOYLPHENYLALANINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-07 | — | — | EP | disclosed |
| EP-1005446-A1 | N-AROYLPHENYLALANINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-07 | — | — | EP | disclosed |
| WO-1999065932-A1 | TETRAPEPTIDES, ANALOGS AND PEPTIDOMIMETICS WHICH BIND SELECTIVELY MAMMALIAN OPIOID RECEPTORS | SEPRACOR, INC. (US) | 1999-12-23 | — | — | WO | disclosed |
| WO-1999010312-A1 | N-ALKANOYLPHENYLALANINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-03-04 | — | — | WO | disclosed |
| WO-1999010313-A1 | N-AROYLPHENYLALANINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177521-A1 | PROCESS FOR THE PREPARATION OF DEGARELIX | VIP, PEPD, SSTR4 | PTGIR 1389/4885FABP5 3455/4885FABP7 4010/4885 |
| US-11773150-B2 | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors | GLP1R, GCG, GCGR | PTGIR 2344/4885FABP5 509/4885FABP7 687/4885 |
| US-11332495-B2 | Process for the preparation of Degarelix acetate and Degarelix acetate-mannitol premix | PEPD, DNPEP, PREP | PTGIR 1310/4885FABP5 4499/4885FABP7 3830/4885 |
| US-20200392197-A1 | ANTIBODY PEPTIDE CONJUGATES THAT HAVE AGONIST ACTIVITY AT BOTH THE GLUCAGON AND GLUCAGON-LIKE PEPTIDE 1 RECEPTORS | GLP1R, GCG, GCGR | PTGIR 2344/4885FABP5 509/4885FABP7 687/4885 |
| US-20020049223-A1 | Quinoline and naphthyridine carboxylic acid antibacterials | NQO2, NQO1, NDUFA7 | PTGIR 4251/4885FABP5 1182/4885FABP7 1540/4885 |
| US-20210094984-A1 | Process for the preparation of Degarelix acetate and Degarelix acetate-mannitol premix | PEPD, DNPEP, PREP | PTGIR 1276/4885FABP5 4521/4885FABP7 3879/4885 |
| US-10800826-B2 | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors | GLP1R, GCG, GCGR | PTGIR 2344/4885FABP5 509/4885FABP7 687/4885 |
| US-20220033443-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | ANPEP, DNPEP, NPPA | PTGIR 1734/4885FABP5 4016/4885FABP7 3762/4885 |
| US-10683334-B2 | Aqueously soluble and chemically stable glucagon peptides | IAPP, GLP1R, GCG | PTGIR 879/4885FABP5 1228/4885FABP7 523/4885 |
| US-12098218-B2 | Process for the manufacture of degarelix and its intermediates | ANPEP, DNPEP, NPPA | PTGIR 1734/4885FABP5 4016/4885FABP7 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.